<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-16992" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>5&#x003b1;-Reductase Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Salisbury</surname>
            <given-names>Blake H.</given-names>
          </name>
          <aff>MSUCHM - Ascension Providence</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Stephen W.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Blake Salisbury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Leslie declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-16992.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">5&#x003b1;-reductase inhibitors (5-ARIs), including finasteride and dutasteride, are approved by the U.S. Food and Drug Administration for treating benign prostatic hyperplasia and androgenic alopecia. These medications inhibit the enzyme 5&#x003b1;-reductase, reducing the conversion of testosterone into dihydrotestosterone, a hormone implicated in prostate enlargement and hair loss. This educational activity&#x000a0;discusses the indications, mechanism of action, potential adverse events, and contraindications associated with 5-ARIs. The activity also covers off-label uses, appropriate dosing recommendations, and monitoring strategies to mitigate drug interactions and ensure patient safety.</p>
        <p>A significant focus is placed on the influence of 5-ARIs on prostate-specific antigen levels and the requisite prostate cancer screening protocols before initiating therapy. Through this activity, healthcare professionals gain&#x000a0;knowledge vital&#x000a0;for optimizing treatment outcomes for patients with conditions like benign prostatic hyperplasia, prostatic bleeding, and alopecia. The goal is to equip healthcare providers with the necessary knowledge to manage these conditions while adhering to safety protocols effectively.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for 5&#x003b1;-reductase inhibitors, such as finasteride and dutasteride, in managing benign prostatic hyperplasia and androgenic alopecia.</p></list-item><list-item><p>Implement standardized protocols for monitoring prostate-specific antigen levels and conducting prostate cancer screening before prescribing 5&#x003b1;-reductase inhibitors.</p></list-item><list-item><p>Apply appropriate dosing recommendations for finasteride and dutasteride based on the indications and patient characteristics.</p></list-item><list-item><p>Implement strategies&#x000a0;with healthcare team members to coordinate comprehensive care for patients receiving 5-ARIs by addressing urological and dermatological concerns.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=16992&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=16992">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-16992.s2" sec-type="Indications">
        <title>Indications</title>
        <p>5&#x003b1;-reductase inhibitors (5-ARIs), specifically finasteride and dutasteride, are medications approved by the U.S. Food and Drug Administration (FDA) for treating 2 conditions: benign prostatic hyperplasia (BPH) and androgenic alopecia (male pattern hair loss).<xref ref-type="bibr" rid="article-16992.r1">[1]</xref><xref ref-type="bibr" rid="article-16992.r2">[2]</xref></p>
        <p>
<bold>
<bold>FDA-Approved Indications</bold>
</bold>
</p>
        <p>
<bold>
<bold>Benign Prostatic Hyperplasia&#x000a0;</bold>
</bold>
</p>
        <p>BPH&#x000a0;is typically seen in older men, and its frequency increases with age. BPH correlates with lower urinary tract symptoms that can cause significant distress, including nocturia, urinary urgency, increased frequency of urination, decreased stream caliber, straining while voiding, intermittency, and a sensation of incomplete bladder emptying.<xref ref-type="bibr" rid="article-16992.r3">[3]</xref></p>
        <p>The symptoms mentioned above can significantly affect the quality of life of patients&#x000a0;with BPH and can cause&#x000a0;severe disruptions in sleeping patterns.&#x000a0;Several theories for the etiology of BPH exist. One widely accepted view involves the androgen dihydrotestosterone (DHT) binding to intracellular androgen receptors in the prostate, leading to increased transcription of proteins responsible for increased cellular proliferation.<xref ref-type="bibr" rid="article-16992.r3">[3]</xref>&#x000a0;DHT is&#x000a0;a hormone that contributes to prostate growth and hair loss. As the gland enlarges, it can compress the prostatic urethra, producing the symptoms described above.</p>
        <p>Both finasteride and dutasteride have&#x000a0;proven effective&#x000a0;for treating BPH. Finasteride reduces prostatic DHT by over 90% and serum DHT by up to 70%; these reductions were dosage-independent.<xref ref-type="bibr" rid="article-16992.r1">[1]</xref><xref ref-type="bibr" rid="article-16992.r4">[4]</xref>&#x000a0;Furthermore, finasteride significantly reduces prostatic volume, which contributes to distressing urinary symptoms.<xref ref-type="bibr" rid="article-16992.r2">[2]</xref><xref ref-type="bibr" rid="article-16992.r5">[5]</xref><xref ref-type="bibr" rid="article-16992.r6">[6]</xref>&#x000a0;Similarly, dutasteride reduces DHT by up to 99% in both the prostate and the serum.&#x000a0;These reductions in prostatic DHT levels significantly decrease serum prostate-specific antigen (PSA) levels by 50% and reduce prostate volume by approximately 25% over time.<xref ref-type="bibr" rid="article-16992.r3">[3]</xref><xref ref-type="bibr" rid="article-16992.r7">[7]</xref>&#x000a0;The majority of PSA reduction occurs within the first 3 months of treatment, while prostate reduction typically takes about 6 months to achieve maximal effect. However,&#x000a0;this may require up to a year.<xref ref-type="bibr" rid="article-16992.r1">[1]</xref><xref ref-type="bibr" rid="article-16992.r7">[7]</xref></p>
        <p>The 50% reduction in PSA levels must be considered when screening for prostate cancer in men who are taking 5-ARIs.<xref ref-type="bibr" rid="article-16992.r8">[8]</xref>&#x000a0;For&#x000a0;instance, if a patient has been on 5-ARIs for 6 months or longer, his PSA level should be doubled for comparative and risk assessment purposes. All patients should be screened&#x000a0;for prostate cancer before initiating treatment with 5-ARIs.<xref ref-type="bibr" rid="article-16992.r8">[8]</xref>&#x000a0;</p>
        <p>BPH is clinically monitored using a symptom score, such as the one published by the American Urological Association (AUA). Symptom scores above 10 points usually indicate further therapy. Patients with&#x000a0;smaller prostates&#x000a0;display better responses to &#x003b1;-blocker medications. In contrast, patients with larger prostates tend to benefit more from 5-ARIs, although this response may take longer to manifest.&#x000a0;In clinical practice, many patients with BPH are initially prescribed &#x003b1;-blockers for immediate symptom relief, with 5-ARIs added for larger prostates or when &#x003b1;-blockers become ineffective.<xref ref-type="bibr" rid="article-16992.r3">[3]</xref><xref ref-type="bibr" rid="article-16992.r9">[9]</xref></p>
        <p>Additionally, 5-ARIs are effective in reducing prostatic bleeding and are often&#x000a0;administered to&#x000a0;patients undergoing transurethral prostate surgery for this purpose.<xref ref-type="bibr" rid="article-16992.r1">[1]</xref><xref ref-type="bibr" rid="article-16992.r10">[10]</xref><xref ref-type="bibr" rid="article-16992.r11">[11]</xref><xref ref-type="bibr" rid="article-16992.r12">[12]</xref><xref ref-type="bibr" rid="article-16992.r13">[13]</xref><xref ref-type="bibr" rid="article-16992.r14">[14]</xref><xref ref-type="bibr" rid="article-16992.r15">[15]</xref>&#x000a0;Although the exact mechanism remains unclear, it is believed to involve a reduction in microvascular density.<xref ref-type="bibr" rid="article-16992.r12">[12]</xref><xref ref-type="bibr" rid="article-16992.r13">[13]</xref><xref ref-type="bibr" rid="article-16992.r14">[14]</xref>&#x000a0;The medication should be initiated at least&#x000a0;2 weeks before surgery to minimize operative and postoperative bleeding.<xref ref-type="bibr" rid="article-16992.r15">[15]</xref></p>
        <p>
<bold>Androgenic Alopecia</bold>
</p>
        <p>Androgenic alopecia, commonly known as male-pattern hair loss, affects millions of men and women globally, affecting approximately 50% of men and potentially an equal number of women aged 40 or older. Additionally, alopecia is reported in up to 13% of premenopausal women to some degree. This condition is associated with significant morbidity, as changes in physical appearance can profoundly affect the patient's well-being.&#x000a0;Androgenic alopecia contributes to a substantial portion of these cases. Hair loss typically begins at the crown of the scalp and advances anteriorly, while the temporal and occipital portions of the head are often spared.<xref ref-type="bibr" rid="article-16992.r16">[16]</xref> This effect is attributed to DHT, which promotes hair miniaturization by interacting with androgen-sensitive receptors.<xref ref-type="bibr" rid="article-16992.r16">[16]</xref></p>
        <p>The follicular response to androgens varies depending on the body's location. For instance, in areas such as the face, androgens stimulate the growth of facial hair, producing anabolic effects. Conversely, the opposite effect occurs in regions such as the scalp's crown (or vertex), leading to diminished hair growth. While male pattern baldness is a natural phenomenon associated with aging, hair loss can evoke emotional distress, particularly among younger populations.</p>
        <p>The&#x000a0;2 most common first-line FDA-approved treatments for male pattern hair loss are topical minoxidil and oral finasteride, with finasteride generally considered more effective.<xref ref-type="bibr" rid="article-16992.r17">[17]</xref>&#x000a0;Although these&#x000a0;medications are effective, they are not cures, as any benefits gained from the treatment are typically lost&#x000a0;after discontinuing them. Hair shedding and loss usually begin around 2 weeks after finasteride discontinuation, with all newly regrown hair being lost within a year.</p>
        <p>Numerous studies have tested the efficacy of oral finasteride&#x000a0;in treating androgenic alopecia, revealing a significant improvement in the condition. However, it may take up to 12 months to achieve maximal effect.</p>
        <list list-type="bullet">
          <list-item>
            <p>A study found that while individuals receiving no treatment for androgenic alopecia experienced a 26% loss in hair count over 5 years, patients treated with finasteride showed a 10% increase within 12 months.<xref ref-type="bibr" rid="article-16992.r2">[2]</xref><xref ref-type="bibr" rid="article-16992.r16">[16]</xref><xref ref-type="bibr" rid="article-16992.r18">[18]</xref><xref ref-type="bibr" rid="article-16992.r19">[19]</xref><xref ref-type="bibr" rid="article-16992.r20">[20]</xref><xref ref-type="bibr" rid="article-16992.r21">[21]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Another study provided evidence of finasteride's effectiveness in managing androgenic alopecia, with all patients demonstrating increased hair count after 12 months of treatment.<xref ref-type="bibr" rid="article-16992.r2">[2]</xref><xref ref-type="bibr" rid="article-16992.r6">[6]</xref><xref ref-type="bibr" rid="article-16992.r16">[16]</xref><xref ref-type="bibr" rid="article-16992.r18">[18]</xref><xref ref-type="bibr" rid="article-16992.r19">[19]</xref><xref ref-type="bibr" rid="article-16992.r20">[20]</xref><xref ref-type="bibr" rid="article-16992.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>Finasteride reduces hair loss in approximately 88% of men and aids in regrowing hair in about 66% of cases. Studies indicate that oral finasteride is more effective than topical minoxidil.<xref ref-type="bibr" rid="article-16992.r17">[17]</xref>&#x000a0;Additionally, combining oral finasteride with topical minoxidil yields superior results to either therapy alone.<xref ref-type="bibr" rid="article-16992.r22">[22]</xref><xref ref-type="bibr" rid="article-16992.r23">[23]</xref><xref ref-type="bibr" rid="article-16992.r24">[24]</xref><xref ref-type="bibr" rid="article-16992.r22">[22]</xref><xref ref-type="bibr" rid="article-16992.r24">[24]</xref>&#x000a0;The combination of topical finasteride and minoxidil has also shown greater efficacy than monotherapy, but it is not FDA-approved in the U.S.<xref ref-type="bibr" rid="article-16992.r23">[23]</xref></p>
        <p>In a comparative study of treatment outcomes, the percentage of men who showed improvement in hair loss after a year of continuous therapy were:<xref ref-type="bibr" rid="article-16992.r24">[24]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Topical minoxidil (5%): 59%</p>
          </list-item>
          <list-item>
            <p>Finasteride oral 1 mg: 80.5%</p>
          </list-item>
          <list-item>
            <p>Combination topical minoxidil and oral finasteride: 94.1%&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Topical finasteride has shown comparable efficacy to the oral formulation but lacks FDA approval for this indication.<xref ref-type="bibr" rid="article-16992.r25">[25]</xref><xref ref-type="bibr" rid="article-16992.r26">[26]</xref><xref ref-type="bibr" rid="article-16992.r27">[27]</xref>&#x000a0;Conversely, oral minoxidil is FDA-approved in the United States for severe hypertension&#x000a0;and is often prescribed off-label for hair loss treatment, where it demonstrates effectiveness.<xref ref-type="bibr" rid="article-16992.r28">[28]</xref></p>
        <p>Dutasteride lacks FDA approval for treating hair loss but is commonly prescribed off-label for alopecia.<xref ref-type="bibr" rid="article-16992.r29">[29]</xref>&#x000a0;Comparative&#x000a0;studies indicate that dutasteride is as effective as (and possibly superior to) finasteride in treating hair loss.<xref ref-type="bibr" rid="article-16992.r29">[29]</xref><xref ref-type="bibr" rid="article-16992.r30">[30]</xref><xref ref-type="bibr" rid="article-16992.r31">[31]</xref><xref ref-type="bibr" rid="article-16992.r32">[32]</xref>&#x000a0;Only topical minoxidil and oral finasteride have been approved by the FDA for male hair loss treatment in the United States.<xref ref-type="bibr" rid="article-16992.r6">[6]</xref><xref ref-type="bibr" rid="article-16992.r16">[16]</xref><xref ref-type="bibr" rid="article-16992.r33">[33]</xref><xref ref-type="bibr" rid="article-16992.r34">[34]</xref></p>
        <p>The longer half-life of dutasteride makes it amenable for scalp microinjection therapy using 0.01% dutasteride solution.<xref ref-type="bibr" rid="article-16992.r21">[21]</xref>&#x000a0;Case studies suggest&#x000a0;efficacy, but randomized controlled trials are lacking.<xref ref-type="bibr" rid="article-16992.r21">[21]</xref><xref ref-type="bibr" rid="article-16992.r35">[35]</xref><xref ref-type="bibr" rid="article-16992.r36">[36]</xref></p>
        <p>5-ARIs have shown efficacy in enhancing overall survival and reducing the incidence of bladder cancer.<xref ref-type="bibr" rid="article-16992.r37">[37]</xref><xref ref-type="bibr" rid="article-16992.r38">[38]</xref><xref ref-type="bibr" rid="article-16992.r39">[39]</xref><xref ref-type="bibr" rid="article-16992.r40">[40]</xref>&#x000a0;Additionally,&#x000a0;existing evidence suggests that men with prostate cancer who take 5-ARIs experience a decreased risk of disease progression.<xref ref-type="bibr" rid="article-16992.r41">[41]</xref>&#x000a0;</p>
        <p>Although not FDA-approved for idiopathic female hirsutism, clinicians have&#x000a0;used 5-ARIs to manage this condition,&#x000a0;with some success.<xref ref-type="bibr" rid="article-16992.r42">[42]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-16992.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The gonads, and to a lesser extent, the adrenal glands, produce androgens through a&#x000a0;process beginning with cholesterol. Once formed, testosterone binds to intracellular androgen receptors throughout the body to exert its effects.&#x000a0;DHT binds to the androgen receptor in the cell's cytoplasm, initiating a pathway that alters nuclear gene expression.<xref ref-type="bibr" rid="article-16992.r43">[43]</xref><xref ref-type="bibr" rid="article-16992.r44">[44]</xref></p>
        <p>DHT, a more potent androgen, is formed from testosterone by the isoenzymes of 5&#x003b1;-reductase (types 1 and 2), primarily found in the scalp and prostate cells. While testosterone and DHT are androgenic steroids, they exert slightly different effects throughout the body. Testosterone is largely responsible for growth during puberty, increased muscle mass, and elevated hematocrit levels in males.<xref ref-type="bibr" rid="article-16992.r45">[45]</xref> In contrast, DHT is crucial in the fetal differentiation of external male genitalia, male hair patterns, and prostatic growth.<xref ref-type="bibr" rid="article-16992.r43">[43]</xref><xref ref-type="bibr" rid="article-16992.r45">[45]</xref><xref ref-type="bibr" rid="article-16992.r46">[46]</xref></p>
        <p>Finasteride and dutasteride are 5-ARIs designed to decrease the intracellular production of DHT.<xref ref-type="bibr" rid="article-16992.r47">[47]</xref>&#x000a0;Although&#x000a0;these drugs are competitive inhibitors of 5&#x003b1;-reductase, finasteride selectively inhibits the type 2 isoenzyme, whereas dutasteride blocks both type 1 and 2 isoenzymes.<xref ref-type="bibr" rid="article-16992.r47">[47]</xref>&#x000a0;A&#x000a0;significant clinical difference between these&#x000a0;2 medications does not exist.<xref ref-type="bibr" rid="article-16992.r47">[47]</xref>&#x000a0;The only clinically significant pharmacological difference is their half-life: 6 to 8 hours for finasteride and 4 to 5 weeks for dutasteride.<xref ref-type="bibr" rid="article-16992.r6">[6]</xref><xref ref-type="bibr" rid="article-16992.r48">[48]</xref><xref ref-type="bibr" rid="article-16992.r49">[49]</xref></p>
        <p>These drugs&#x000a0;are prescribed&#x000a0;to&#x000a0;reduce male pattern hair loss in androgenic alopecia as well as prostatic growth and size in BPH.<xref ref-type="bibr" rid="article-16992.r45">[45]</xref>&#x000a0;A recent meta-analysis demonstrated that oral 5-ARIs are more effective than minoxidil or newer treatment modalities like botulinum toxin, microneedling, and photobiomodulation for&#x000a0;managing androgenetic alopecia.<xref ref-type="bibr" rid="article-16992.r50">[50]</xref></p>
      </sec>
      <sec id="article-16992.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Available Dosage Forms and Strengths:&#x000a0;</bold>Finasteride is available in 1 mg and 5 mg tablets.&#x000a0;Dutasteride is available in 0.5 mg capsules.</p>
        <p><bold>Adult Dosage:&#x000a0;</bold>The standard daily dosage of finasteride is 1 mg for androgenic alopecia and 5 mg for BPH. The standard dosage of dutasteride is 0.5 mg once daily.</p>
      </sec>
      <sec id="article-16992.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The reported adverse effects of 5-ARIs are primarily sexual and include erectile dysfunction, reduced ejaculatory volume, decreased libido, and gynecomastia. These symptoms are believed to be caused by reduced DHT levels and the shunting of testosterone to estradiol.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Finasteride and dutasteride inhibit 5&#x003b1;-reductase, which converts testosterone to DHT, increasing serum testosterone levels. Excess testosterone is then converted into estradiol by aromatase, which can result in gynecomastia. Orthostatic hypotension has also been documented in patients taking 5-ARIs. As dutasteride is often taken with tamsulosin, an &#x003b1;-1 blocker, reports of orthostatic hypotension, dizziness, and weakness have been documented.<xref ref-type="bibr" rid="article-16992.r6">[6]</xref></p>
        <p>In rare instances, adverse effects have persisted even after discontinuing treatment. This condition is known as post-finasteride syndrome, and ongoing research aims to deepen our understanding of this disorder. Additionally, 5-ARIs may be associated with&#x000a0;reduced fertility. However, this effect is reversible upon cessation of treatment, and patients often maintain the ability to conceive while taking 5-ARIs.<xref ref-type="bibr" rid="article-16992.r51">[51]</xref>&#x000a0;Notably, &#x003b1;-blockers, frequently prescribed alongside 5-ARIs, can interfere with ejaculation.<xref ref-type="bibr" rid="article-16992.r52">[52]</xref><xref ref-type="bibr" rid="article-16992.r53">[53]</xref></p>
        <p>Post-finasteride syndrome encompasses a range of adverse effects linked to the discontinuation of finasteride or dutasteride. These adverse effects may persist and involve ongoing mental, neurological, physical, or sexual dysfunction. Almost all cases include sexual dysfunction, with reports also indicating increased anxiety, depression, and suicidal ideations among men who cease 5-ARI therapy. Currently, treatment for this disorder does not exist.<xref ref-type="bibr" rid="article-16992.r54">[54]</xref><xref ref-type="bibr" rid="article-16992.r55">[55]</xref><xref ref-type="bibr" rid="article-16992.r56">[56]</xref><xref ref-type="bibr" rid="article-16992.r57">[57]</xref><xref ref-type="bibr" rid="article-16992.r58">[58]</xref></p>
      </sec>
      <sec id="article-16992.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>5-ARIs&#x000a0;cause reduced levels of DHT, a critical androgen in sexual development. Therefore, children and pregnant or intending-to-be-pregnant women should refrain from using these drugs.<xref ref-type="bibr" rid="article-16992.r59">[59]</xref>&#x000a0;Additionally, individuals with a known hypersensitivity reaction to these drugs should avoid their use.<xref ref-type="bibr" rid="article-16992.r6">[6]</xref></p>
      </sec>
      <sec id="article-16992.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Guidelines for monitoring responses to 5-ARIs do not exist. However, PSA concentrations can be valuable in evaluating the treatment of BPH. As the prostate typically produces elevated PSA in patients with BPH, reductions in prostatic volume lead to decreased PSA concentrations. The efficacy of 5-ARIs can be evaluated by measuring PSA concentrations.<xref ref-type="bibr" rid="article-16992.r6">[6]</xref><xref ref-type="bibr" rid="article-16992.r60">[60]</xref></p>
        <p>Several controversial studies have emerged suggesting a potential association between finasteride use and prostate cancer. Notably, the Prostate Cancer Prevention Trial investigated the prevalence of prostate cancer in men 55 or older on finasteride therapy. While this trial reported a 25% reduction in prostate cancer prevalence, it also noted an increased incidence of high-grade prostate cancer.<xref ref-type="bibr" rid="article-16992.r61">[61]</xref>&#x000a0;As a result, the FDA issued a boxed warning for finasteride in response to these findings.<xref ref-type="bibr" rid="article-16992.r62">[62]</xref>&#x000a0;However, subsequent studies have contradicted this, reporting no actual increased risk of prostate cancer in patients taking finasteride or dutasteride.<xref ref-type="bibr" rid="article-16992.r63">[63]</xref><xref ref-type="bibr" rid="article-16992.r64">[64]</xref><xref ref-type="bibr" rid="article-16992.r65">[65]</xref><xref ref-type="bibr" rid="article-16992.r66">[66]</xref></p>
        <p>For patients who have been on these drugs for 6 months or longer, measured PSA levels should be doubled to account for the effect of 5-ARIs.<xref ref-type="bibr" rid="article-16992.r3">[3]</xref><xref ref-type="bibr" rid="article-16992.r7">[7]</xref></p>
      </sec>
      <sec id="article-16992.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Reports of toxicity related to 5-ARIs have not been documented.</p>
      </sec>
      <sec id="article-16992.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The 5&#x003b1;-reductase inhibitors (finasteride and dutasteride) are effective treatments for both BPH and androgenic alopecia. Given the longer duration of symptom relief, patient education by nurses, pharmacists, and physicians is crucial to ensure adherence. Patients should be thoroughly informed about potential adverse effects and screened for prostate cancer before starting these medications.</p>
      </sec>
      <sec id="article-16992.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=16992&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=16992">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/16992/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=16992">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-16992.s11">
        <title>References</title>
        <ref id="article-16992.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Finasteride in the treatment of patients with benign prostatic hyperplasia: a review.</article-title>
            <source>Ther Clin Risk Manag</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>535</fpage>
            <page-range>535-45</page-range>
            <pub-id pub-id-type="pmid">19707263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WI</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system.</article-title>
            <source>J Dermatol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-143</page-range>
            <pub-id pub-id-type="pmid">30536893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Baradhi</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <chapter-title>Benign Prostatic Hyperplasia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">32644346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norman</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Coakes</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Rittmaster</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Androgen metabolism in men receiving finasteride before prostatectomy.</article-title>
            <source>J Urol</source>
            <year>1993</year>
            <month>Nov</month>
            <volume>150</volume>
            <issue>5 Pt 2</issue>
            <fpage>1736</fpage>
            <page-range>1736-9</page-range>
            <pub-id pub-id-type="pmid">7692110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <source>Treatments for Benign Prostatic Hyperplasia [Internet]</source>
            <publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name>
            <publisher-loc>Rockville (MD)</publisher-loc>
            <year>2004</year>
            <month>08</month>
            <day>02</day>
            <pub-id pub-id-type="pmid">25879123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Zito</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Bistas</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Finasteride</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">30020701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hernandez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gelfond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liss</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ankerst</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>e0204823</fpage>
            <pub-id pub-id-type="pmid">30300367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jain</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sapra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Prostate Cancer Screening</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32310541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Nachawati</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <chapter-title>Alpha-Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">32310526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Puchner</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report.</article-title>
            <source>J Urol</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>154</volume>
            <issue>5</issue>
            <fpage>1779</fpage>
            <page-range>1779-82</page-range>
            <pub-id pub-id-type="pmid">7563345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Puchner</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up.</article-title>
            <source>Urology</source>
            <year>1998</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-40</page-range>
            <pub-id pub-id-type="pmid">9495704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foley</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Soloman</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Wedderburn</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Kashif</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Summerton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Basketter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride.</article-title>
            <source>J Urol</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>163</volume>
            <issue>2</issue>
            <fpage>496</fpage>
            <page-range>496-8</page-range>
            <pub-id pub-id-type="pmid">10647664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donohue</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Hayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karnik</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks.</article-title>
            <source>BJU Int</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>96</volume>
            <issue>9</issue>
            <fpage>1319</fpage>
            <page-range>1319-22</page-range>
            <pub-id pub-id-type="pmid">16287453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Memis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ozden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ozdal</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Guzel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Seckin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.</article-title>
            <source>Urol Int</source>
            <year>2008</year>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-80</page-range>
            <pub-id pub-id-type="pmid">18362489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozdal</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Ozden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Benli</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>G&#x000f6;kkaya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bulut</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Memi&#x0015f;</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study.</article-title>
            <source>Prostate Cancer Prostatic Dis</source>
            <year>2005</year>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-8</page-range>
            <pub-id pub-id-type="pmid">15999118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ho</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zito</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <chapter-title>Androgenetic Alopecia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">28613674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>A&#x000e7;ikg&#x000f6;z</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ta&#x0015f;tan</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>K&#x000f6;se</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kurumlu</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.</article-title>
            <source>Dermatology</source>
            <year>2004</year>
            <volume>209</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-25</page-range>
            <pub-id pub-id-type="pmid">15316165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasaki</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Review of Human Hair Follicle Biology: Dynamics of Niches and Stem Cell Regulation for Possible Therapeutic Hair Stimulation for Plastic Surgeons.</article-title>
            <source>Aesthetic Plast Surg</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>253</fpage>
            <page-range>253-266</page-range>
            <pub-id pub-id-type="pmid">30324295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r19">
          <label>19</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Asfour</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cranwell</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Male Androgenetic Alopecia</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">25905192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stough</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Finasteride improves male pattern hair loss in a randomized study in identical twins.</article-title>
            <source>Eur J Dermatol</source>
            <year>2002</year>
            <season>Jan-Feb</season>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-7</page-range>
            <pub-id pub-id-type="pmid">11809593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Courtney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Triwongwarant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chim</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Eisman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sinclair</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2023</year>
            <season>Sep-Dec</season>
            <volume>24</volume>
            <issue>18</issue>
            <fpage>1919</fpage>
            <page-range>1919-1922</page-range>
            <pub-id pub-id-type="pmid">37942878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy and Safety of Finasteride Combined with Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-analysis.</article-title>
            <source>Aesthetic Plast Surg</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>962</fpage>
            <page-range>962-970</page-range>
            <pub-id pub-id-type="pmid">32166351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Caro</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor blinded, 3-arm, pilot trial.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>502</fpage>
            <page-range>502-509</page-range>
            <pub-id pub-id-type="pmid">37798906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rui</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients.</article-title>
            <source>Dermatol Ther</source>
            <year>2015</year>
            <season>Sep-Oct</season>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-8</page-range>
            <pub-id pub-id-type="pmid">26031764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abeck</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>K&#x000f6;tt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garrahy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Veneroso</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>R&#x000fc;nger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Torster</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>von B&#x000fc;ren</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Patient-reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2024</year>
            <month>May</month>
            <day>07</day>
            <pub-id pub-id-type="pmid">38713003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keerti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madke</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Keerti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>MJC</given-names>
              </name>
              <name>
                <surname>Lirio</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Topical Finasteride: A Comprehensive Review of Androgenetic Alopecia Management for Men and Women.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>e44949</fpage>
            <pub-id pub-id-type="pmid">37818522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piraccini</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Blume-Peytavi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Scarci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jansat</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Falqu&#x000e9;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Otero</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tamarit</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Galv&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tebbs</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Massana</surname>
                <given-names>E</given-names>
              </name>
              <collab>Topical Finasteride Study Group</collab>
            </person-group>
            <article-title>Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>286</fpage>
            <page-range>286-294</page-range>
            <pub-id pub-id-type="pmid">34634163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Talukder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shemer</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of low-dose oral minoxidil in the management of androgenetic alopecia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-147</page-range>
            <pub-id pub-id-type="pmid">38315101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arif</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dorjay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Adil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sami</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Dutasteride in Androgenetic Alopecia: An Update.</article-title>
            <source>Curr Clin Pharmacol</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-35</page-range>
            <pub-id pub-id-type="pmid">28294070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhurat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rudnicka</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kroumpouzos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kassir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galadari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wollina</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lotti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Golubovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Binic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Grabbe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldust</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.</article-title>
            <source>Dermatol Ther</source>
            <year>2020</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>e13379</fpage>
            <pub-id pub-id-type="pmid">32279398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Long-term efficacy and safety of dutasteride 0.5&#x02009;mg in Korean men with androgenetic alopecia: 5-year data demonstrating clinical improvement with sustained efficacy.</article-title>
            <source>J Dermatol</source>
            <year>2024</year>
            <month>May</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>684</fpage>
            <page-range>684-690</page-range>
            <pub-id pub-id-type="pmid">38321615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Talukder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>2946</fpage>
            <page-range>2946-2962</page-range>
            <pub-id pub-id-type="pmid">35920739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Talukder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Emerging and traditional 5-&#x003b1; reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia.</article-title>
            <source>Expert Opin Emerg Drugs</source>
            <year>2024</year>
            <month>Apr</month>
            <day>26</day>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">38666717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kumar D</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Minoxidil</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>5</month>
            <day>9</day>
            <pub-id pub-id-type="pmid">29494000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saceda-Corralo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moustafa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moreno-Arrones</surname>
                <given-names>&#x000d3;</given-names>
              </name>
              <name>
                <surname>Ja&#x000e9;n-Olasolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Va&#x000f1;&#x000f3;-Galv&#x000e1;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Camacho</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice.</article-title>
            <source>J Drugs Dermatol</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>742</fpage>
            <page-range>742-747</page-range>
            <pub-id pub-id-type="pmid">35816059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez-Cuadrado</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Pinto-Pulido</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Parrado</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature.</article-title>
            <source>Eur J Dermatol</source>
            <year>2023</year>
            <month>Feb</month>
            <day>01</day>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <pub-id pub-id-type="pmid">37178048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Effects of androgen suppression therapy on the incidence and prognosis of bladder cancer: An updated systematic review and meta-analysis.</article-title>
            <source>Urol Oncol</source>
            <year>2024</year>
            <month>May</month>
            <day>09</day>
            <pub-id pub-id-type="pmid">38729866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pyun</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Son</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study.</article-title>
            <source>World J Mens Health</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>460</fpage>
            <page-range>460-466</page-range>
            <pub-id pub-id-type="pmid">38164032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>An</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Noh</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Joo</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Kwak</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Association of 5&#x003b1;-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.</article-title>
            <source>JAMA Netw Open</source>
            <year>2023</year>
            <month>May</month>
            <day>01</day>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>e2313667</fpage>
            <pub-id pub-id-type="pmid">37191958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Dursun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Pruthi</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Kaushik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Svatek</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Liss</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis.</article-title>
            <source>Clin Genitourin Cancer</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>314.e1</fpage>
            <page-range>314.e1-314.e7</page-range>
            <pub-id pub-id-type="pmid">36402643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsukawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yanagisawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bekku</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Parizi</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Laukhtina</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Klemm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chiujdea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pradere</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rivas</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Gandaglia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kasivisvanathan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ploussard</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cornford</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shariat</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Rajwa</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis.</article-title>
            <source>Eur Urol Oncol</source>
            <year>2024</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>376</fpage>
            <page-range>376-400</page-range>
            <pub-id pub-id-type="pmid">38277189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moghetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Castello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Magnani</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Tosi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Armanini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bellotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Muggeo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>1115</fpage>
            <page-range>1115-21</page-range>
            <pub-id pub-id-type="pmid">7962284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r43">
          <label>43</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kinter</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Amraei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anekar</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <chapter-title>Biochemistry, Dihydrotestosterone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">32491566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchetti</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Clinical biochemistry of dihydrotestosterone.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>Pt 2</issue>
            <fpage>95</fpage>
            <page-range>95-107</page-range>
            <pub-id pub-id-type="pmid">23431485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r45">
          <label>45</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Nassar</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Physiology, Testosterone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">30252384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basaria</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reproductive aging in men.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>255</fpage>
            <page-range>255-70</page-range>
            <pub-id pub-id-type="pmid">23702400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nickel</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Comparison of clinical trials with finasteride and dutasteride.</article-title>
            <source>Rev Urol</source>
            <year>2004</year>
            <volume>6 Suppl 9</volume>
            <issue>Suppl 9</issue>
            <fpage>S31</fpage>
            <page-range>S31-9</page-range>
            <pub-id pub-id-type="pmid">16985923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erdemir</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Harbin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hellstrom</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>5-alpha reductase inhibitors and erectile dysfunction: the connection.</article-title>
            <source>J Sex Med</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>2917</fpage>
            <page-range>2917-24</page-range>
            <pub-id pub-id-type="pmid">19090946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gisleskog</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Hermann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hammarlund-Udenaes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>MO</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-8</page-range>
            <pub-id pub-id-type="pmid">10073740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bamimore</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Talukder</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The impact of monotherapies for male androgenetic alopecia: A network meta-analysis study.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2024</year>
            <month>May</month>
            <day>09</day>
            <pub-id pub-id-type="pmid">38725143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Why Odds Ratios Can Be Tricky Statistics: The Case of Finasteride, Dutasteride, and Sexual Dysfunction.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2018</year>
            <month>Nov</month>
            <day>27</day>
            <volume>79</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">30549493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bearelly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avellino</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction.</article-title>
            <source>Fertil Steril</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>116</volume>
            <issue>3</issue>
            <fpage>611</fpage>
            <page-range>611-617</page-range>
            <pub-id pub-id-type="pmid">34462095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bapir</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhatti</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Eliwa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Perdomo</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Gherabi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hennessey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Magri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mourmouris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ouattara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perletti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Philipraj</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trinchieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis.</article-title>
            <source>Arch Ital Urol Androl</source>
            <year>2022</year>
            <month>Jun</month>
            <day>30</day>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-263</page-range>
            <pub-id pub-id-type="pmid">35775356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traish</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Post-finasteride syndrome: a surmountable challenge for clinicians.</article-title>
            <source>Fertil Steril</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-50</page-range>
            <pub-id pub-id-type="pmid">32033719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coskuner</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Ozkan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Culha</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors.</article-title>
            <source>Sex Med Rev</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>277</fpage>
            <page-range>277-282</page-range>
            <pub-id pub-id-type="pmid">30301703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Said</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Impact of 5&#x003b1;-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health.</article-title>
            <source>Curr Urol Rep</source>
            <year>2018</year>
            <month>Jun</month>
            <day>16</day>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>65</fpage>
            <pub-id pub-id-type="pmid">29909472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fertig</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Gamret</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Darwin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaudi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Sexual side effects of 5-&#x003b1;-reductase inhibitors finasteride and dutasteride: A comprehensive review.</article-title>
            <source>Dermatol Online J</source>
            <year>2017</year>
            <month>Nov</month>
            <day>11</day>
            <volume>23</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">29447628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-17</page-range>
            <pub-id pub-id-type="pmid">30206635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teichert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Puijenbroek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stricker</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Contraindicated use of 5-alpha-reductase inhibitors in women.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>83</volume>
            <issue>2</issue>
            <fpage>429</fpage>
            <page-range>429-431</page-range>
            <pub-id pub-id-type="pmid">27567019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mirna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rachita</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maja</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Aseem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zeljana</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Controversies in the treatment of androgenetic alopecia: The history of finasteride.</article-title>
            <source>Dermatol Ther</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>e12647</fpage>
            <pub-id pub-id-type="pmid">30253001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tangen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Darke</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lucia</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Minasian</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Parnes</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>LeBlanc</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Effects of Finasteride on Prostate Cancer Mortality.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>24</day>
            <volume>380</volume>
            <issue>4</issue>
            <fpage>393</fpage>
            <page-range>393-394</page-range>
            <pub-id pub-id-type="pmid">30673548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Karna</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia.</article-title>
            <source>World J Mens Health</source>
            <year>2019</year>
            <month>May</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-165</page-range>
            <pub-id pub-id-type="pmid">30209896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirshburg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kelsey</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Therrien</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gavino</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Reichenberg</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>7</issue>
            <fpage>56</fpage>
            <page-range>56-62</page-range>
            <pub-id pub-id-type="pmid">27672412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonde Miranda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Garmo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stattin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>5&#x003b1;-Reductase Inhibitors and Risk of Prostate Cancer Death.</article-title>
            <source>J Urol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>204</volume>
            <issue>4</issue>
            <fpage>714</fpage>
            <page-range>714-719</page-range>
            <pub-id pub-id-type="pmid">32243243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaselkiv</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ceraolo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Pernar</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Rencsok</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stopsack</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Plym</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Olumi</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Kibel</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mucci</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>5-Alpha Reductase Inhibitors and Prostate Cancer Mortality among Men with Regular Access to Screening and Health Care.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2022</year>
            <month>Jul</month>
            <day>01</day>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>1460</fpage>
            <page-range>1460-1465</page-range>
            <pub-id pub-id-type="pmid">35255119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-16992.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Till</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Tangen</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Ramsey</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Minasian</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Hershman</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">27565902</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
